Olanzapine-Associated Weight Gain in Healthy Males
P.I. Dr. Dubovsky
Co-Investigators: Drs. Ed Bednarczyk, Leonard Epstein, Kenneth Leonard, John Leddy, Paresh Dandona, Manish Upadhyay, Elsa Daurignac
Internally Sponsored Research

Olanzapine is associated with weight gain, hyperlipidemia, and type II diabetes among psychiatric patients.  Our studies are designed to gather data regarding the processes that potentially underly these effects, but among individuals without major psychiatric disorders. We will determine whether olanzapine is associated with changes in weight, dietary intake, food reinforcement value, physical activity, D2 receptor availability, glucose tolerance, insulin responsiveness, and inflammatory response. Further, we will examine the effect of the dopamine transporter gene polymorphism (SLC6A3), the dopamine D2 receptor gene polymorphism (DRD2), and the hydroxytrytamine 2c (5-HT2c) receptor gene polymorphism (-759 T/C) on food intake and weight gain during olanzapine treatment.